SCT-1000
- Generic Name
- SCT-1000
A Phase I Safty and Immunogenicity Study of SCT1000 in Healthy Women Aged 18 to 45 Years
Phase 1
- Conditions
- HPV Infection Vaccine Safety SCT1000
- Interventions
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2021-09-17
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT04921111
- Locations
- 🇨🇳
Guanyun Country CDC, Nanjing, Jiangsu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath